Bachem, a leading Swiss manufacturer of peptides and oligonucleotides, reported robust financial results for the first half of 2025 and unveiled plans to invest USD 460 million over the year to expand its global manufacturing footprint.

The company recorded a 17.9% year-on-year increase in sales, reaching CHF 318.8 million, driven by strong demand across its commercial and CMO segments. Operating profit also saw a significant rise, with an EBIT margin of 19.3%, reflecting improved productivity and operational efficiency.

Bachem announced that its planned investments will support capacity expansion at its sites in Switzerland, the US, and the UK. These investments are aimed at meeting growing demand for complex active pharmaceutical ingredients (APIs), particularly in the biotech sector.

CEO Thomas Meier stated that Bachem is well-positioned to capitalise on emerging opportunities in peptide therapeutics and oligonucleotide manufacturing.